The EMA has updated its practical guidance for pharmaceutical companies for procedures related to Brexit

From 30th March 2019, when the United Kingdom’s (U.K.) is expected to withdraw from the European Union (EU), all EU law will no longer apply to the U.K. The European Medicines Agency (EMA) and the European Commission have therefore published additional practical guidance to help pharmaceutical companies legally prepare for this transition. This guidance will…

EMA and EUnetHTA publish a 3 year collaboration plan to improve efficiency and quality

The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have finalised “a joint work plan outlining key areas of collaboration for the next three years”. The main areas of collaboration are information exchange at market entry, data generation post approval and early dialogue. These areas are expected to also provide…

Partners4Access launch weekly newsletter focusing on market access and rare diseases

Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market access landscape. The service will offer a comprehensive weekly summary of the most interesting and relevant news articles, beginning on Thursday 16th November 2017. The newsletter will allow readers to…

P4A’s Sophie Schmitz presents key insights on Gene Therapy at WODC 2017

Sophie Schmitz, Managing Partner of Partners4Access, the specialists in orphan drug access, is presenting at the 8th annual meeting of the World Orphan Drug Congress in Barcelona on November 15, 2017 on Gene Therapy. Schmitz will be reviewing the potential of Gene Therapy to revolutionise the healthcare industry, highlighting recent successes and discussing key challenges. “Gene…